Targeting HPV E6-Dependent Hypoxia-Induced NF-kappa B in Cervical Cancer
靶向宫颈癌中 HPV E6 依赖性缺氧诱导的 NF-κ B
基本信息
- 批准号:7927183
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-10-01 至 2015-09-30
- 项目状态:已结题
- 来源:
- 关键词:2-oxoglutarate 3-dioxygenase prolineAccountingAffectAmino Acid MotifsAmino AcidsAnusBiochemicalCMV promoterCancer EtiologyCancer PatientCancer cell lineCervicalClinicalClinical TrialsComplexCuesDevelopmentDisciplineDiseaseEctopic ExpressionEnhancersEventFemaleGenderGene ExpressionGoalsGrowthGynecologic OncologyGynecologic PathologyHPV-High RiskHealthHematogenousHumanHuman PapillomavirusHuman papilloma virus infectionHypoxiaIkappaB kinaseInfectionInjection of therapeutic agentLinkLocationLymphaticLysineMalignant NeoplasmsMalignant neoplasm of cervix uteriMeasurementMeasuresMediatingMedical OncologyMetastatic Neoplasm to the LungMilitary PersonnelMissionMixed Function OxygenasesModelingMolecularMolecular TargetMusMutagenesisNF-kappa BNFKB Signaling PathwayNeoplasm MetastasisNude MiceOutcomeOxygenPartial PressurePathway interactionsPatientsPhasePhenotypePhysiciansPimonidazolePlayPolyubiquitinPolyubiquitinationPositioning AttributeProteinsPublishingRadiationRecruitment ActivityRecurrenceRegulationRelative (related person)ResearchResistanceResponse ElementsRoleSamplingScientistSerotypingSignal PathwaySignal TransductionSpecimenStaining methodStainsSystemTNF Receptor-Associated FactorsTailTherapeutic IndexTranslatingTumor Suppressor ProteinsUbiquitinUbiquitinationVaccinationVaccinesVeinsVeteransVulvaWomanWomen&aposs HealthWorkXenograft ModelXenograft procedureangiogenesisbasecancer cellcarcinogenesiscell typechemotherapyclinical phenotypecohortdriving forcehigh riskin vivoinhibitor/antagonistmalemalignant oropharynx neoplasmmortalitymulticatalytic endopeptidase complexpenisprogramsskillssocioeconomicstumortumorigenesis
项目摘要
DESCRIPTION (provided by applicant):
PROJECT ABSTRACT Cervical cancer is the leading cause of cancer-specific mortality amongst women worldwide and the human papilloma virus (HPV) plays a pathophysiologic role in cervical carcinogenesis in over 95% of cases. For over half a century, it has become increasingly established that intratumoral hypoxia is associated with an aggressive clinical phenotype, manifested by resistance to radiation and chemotherapy, a high risk of recurrence and metastasis, and shortened overall survival. The mechanistic underpinnings that account for these adverse clinical sequelae of hypoxia have not been elucidated. We recently identified a biochemical link between HPV infection and hypoxia in cervical cancer (Cancer Cell, 14:394, 2008). Specifically, we found that the HPV-encoded E6 protein mediates prolonged activation of the NF kappa B (NF-:B) signaling pathway under hypoxic conditions. As oxygen becomes a limiting substrate, E6 effectively targets CYLD, a negative regulator of the NF-:B pathway, for proteasome-mediated degradation, and thereby allows for unrestricted NF-:B activation. Through its transcriptional activity, NF-:B drives proliferation, survival, neo-angiogenesis, invasion and metastasis. Thus, we postulate that the poor clinical outcomes associated with hypoxia can in large part be attributed to E6-mediated, hypoxia-induced NF- :B activation. In pursuit of our hypothesis, we propose three aims in which we will be: 1) elucidating some of the key remaining biochemical and molecular cues that drive the E6-CYLD interaction (Specific Aim 1), 2) examining the relative effects of hypoxia-induced versus constitutive NF-:B activation on cervical tumorigenesis and metastasis development in murine xenografts models (Specific Aim 2), and 3) prospectively studying the relationship between hypoxia and NF-:B activation and CYLD expression in tumors of cervical cancer patients (Specific Aim 3). We have assembled a team of physician-scientists with diverse skill sets from various disciplines, including medical oncology, gynecologic oncology, and gynecologic pathology to further our molecular understanding of the hypoxic phenotype. Accomplishments from this proposal represent a necessary prelude to translate our work to early phase clinical trials aimed at targeting hypoxia-induced NF-:B activation, which can take advantage of the potentially high therapeutic index afforded by HPV positivity.
描述(由申请人提供):
项目摘要宫颈癌是全球女性癌症特异性死亡率的主要原因,而人类乳头状瘤病毒(HPV)在超过95%的病例中在宫颈癌中起病理生理作用。在半个多世纪的时间里,越来越多地确定肿瘤内缺氧与积极的临床表型有关,这表现为对放射和化学疗法的抗性,复发和转移的高风险,并缩短了总体生存。尚未阐明这些不良临床后遗症的机械基础尚未阐明。 我们最近确定了HPV感染与宫颈癌缺氧之间的生化联系(Cancer Cell,14:394,2008)。具体而言,我们发现HPV编码的E6蛋白在低氧条件下介导了NF Kappa B(NF-:B)信号通路的延长激活。随着氧成为有限的底物,E6有效地靶向CYLD,CYLD是NF-:B途径的负调节剂,用于蛋白酶体介导的降解,从而允许无限制的NF-:B激活。通过其转录活性,NF-:B驱动增殖,生存,新血管生成,入侵和转移。因此,我们假设与缺氧相关的较差的临床结果可能归因于E6介导的缺氧诱导的NF-:B激活。为了追求我们的假设,我们提出了三个目标:1)阐明剩余的某些生物化学和分子提示的关键,这些关键驱动E6-cyld相互作用(特定目的1),2)检查缺氧引起的低氧相对效果,构建量子和牛乳属性图2) 3)前瞻性研究宫颈癌患者肿瘤中缺氧与NF-激活与CYLD表达之间的关系(特定目标3)。我们已经组建了一支来自各种学科的医师科学家团队,包括医学肿瘤学,妇科肿瘤学和妇科病理学,以进一步了解我们对低氧表型的分子理解。该提案的成就是将我们的工作转化为旨在靶向缺氧引起的NF-:B激活的早期临床试验的必要前奏,该试验可以利用HPV阳性提供的潜在高治疗指数。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MATTHEW B RETTIG其他文献
MATTHEW B RETTIG的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MATTHEW B RETTIG', 18)}}的其他基金
A Phase 2 study of a Checkpoint Inhibitor in Men with Progressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation
一项检查点抑制剂治疗以错配修复缺陷或双等位基因 CDK12 失活为特征的进行性转移性去势抵抗性前列腺癌男性的 2 期研究
- 批准号:
10917011 - 财政年份:2020
- 资助金额:
-- - 项目类别:
A Phase 2 study of a Checkpoint Inhibitor in Men with Progressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation
一项检查点抑制剂治疗以错配修复缺陷或双等位基因 CDK12 失活为特征的进行性转移性去势抵抗性前列腺癌男性的 2 期研究
- 批准号:
10417047 - 财政年份:2020
- 资助金额:
-- - 项目类别:
HIF-alpha-independent Druggable Targets in Renal Cell Carcinoma
肾细胞癌中不依赖 HIF-α 的药物靶点
- 批准号:
9487898 - 财政年份:2015
- 资助金额:
-- - 项目类别:
HIF-alpha-independent Druggable Targets in Renal Cell Carcinoma
肾细胞癌中不依赖 HIF-α 的药物靶点
- 批准号:
8921769 - 财政年份:2015
- 资助金额:
-- - 项目类别:
Identification of Inhibitors of the N-Terminal Region of the Androgen Receptor
雄激素受体 N 末端区域抑制剂的鉴定
- 批准号:
8551641 - 财政年份:2012
- 资助金额:
-- - 项目类别:
Identification of Inhibitors of the N-Terminal Region of the Androgen Receptor
雄激素受体 N 末端区域抑制剂的鉴定
- 批准号:
9097575 - 财政年份:2012
- 资助金额:
-- - 项目类别:
Identification of Inhibitors of the N-Terminal Region of the Androgen Receptor
雄激素受体 N 末端区域抑制剂的鉴定
- 批准号:
8699713 - 财政年份:2012
- 资助金额:
-- - 项目类别:
Identification of Inhibitors of the N-Terminal Region of the Androgen Receptor
雄激素受体 N 末端区域抑制剂的鉴定
- 批准号:
8912402 - 财政年份:2012
- 资助金额:
-- - 项目类别:
Identification of Inhibitors of the N-Terminal Region of the Androgen Receptor
雄激素受体 N 末端区域抑制剂的鉴定
- 批准号:
8373260 - 财政年份:2012
- 资助金额:
-- - 项目类别:
Targeting HPV E6-Dependent Hypoxia-Induced NF-kappa B in Cervical Cancer
靶向宫颈癌中 HPV E6 依赖性缺氧诱导的 NF-κ B
- 批准号:
8413407 - 财政年份:2011
- 资助金额:
-- - 项目类别:
相似国自然基金
环境治理目标下的公司财务、会计和审计行为研究
- 批准号:72332002
- 批准年份:2023
- 资助金额:165.00 万元
- 项目类别:重点项目
信用信息共享机制对企业会计稳健性、风险行为决策以及失信后果的影响研究
- 批准号:72302198
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
套期会计有效性的研究:实证检验及影响机制
- 批准号:72302225
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
新证券法对证券审计市场格局和会计师事务所行为策略的影响研究
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
新证券法对证券审计市场格局和会计师事务所行为策略的影响研究
- 批准号:72202176
- 批准年份:2022
- 资助金额:30.00 万元
- 项目类别:青年科学基金项目
相似海外基金
Targeting HPV E6-Dependent Hypoxia-Induced NF-kappa B in Cervical Cancer
靶向宫颈癌中 HPV E6 依赖性缺氧诱导的 NF-κ B
- 批准号:
8413407 - 财政年份:2011
- 资助金额:
-- - 项目类别:
The Role of FKBP10 in Recessive Osteogenesis Imperfecta
FKBP10 在隐性成骨不全症中的作用
- 批准号:
8253962 - 财政年份:2011
- 资助金额:
-- - 项目类别:
The Role of FKBP10 in Recessive Osteogenesis Imperfecta
FKBP10 在隐性成骨不全症中的作用
- 批准号:
8331763 - 财政年份:2011
- 资助金额:
-- - 项目类别:
The Role of FKBP10 in Recessive Osteogenesis Imperfecta
FKBP10 在隐性成骨不全症中的作用
- 批准号:
8513969 - 财政年份:2011
- 资助金额:
-- - 项目类别:
Project 1. PROLY 3-HYDROXYLASE (P3H) COMPLEX AND MATRIX CELL SIGNALING DEFECTS IN
项目 1. PROLY 3-羟化酶 (P3H) 复合物和基质细胞信号传导缺陷
- 批准号:
8508691 - 财政年份:
- 资助金额:
-- - 项目类别: